Blood cancer charity Anthony Nolan’s Cell & Gene Therapy Services and the Medical Technology Innovation Facility (MTIF) have entered into a Memorandum of Understanding (MoU) to accelerate the development of innovative cell therapies to improve the lives of patients.
Together, they provide a centralised hub of knowledge and development capability that can guide researchers and companies working at the cutting edge of cell and gene therapy from early stage concept to commercialisation.
The £23 million MTIF benefited from a £9.7 million contribution from D2N2s Local Growth Fund allocation and is based at Nottingham Trent University’s Clifton Campus alongside The Anthony Nolan Cell Therapy Centre and Cord Blood Bank, making for the ideal environment to collaborate on projects and capitalise on the combined expertise and facilities of each organisation.
Anthony Nolan Cell & Gene Therapy Services provides ethically-approved, high-quality starting materials to clients, helping them to source the right cellular material at the right time.
MTIF offers a broad range of research and development services for medical technologies, including medical devices, cell & tissue therapies and pharmaceuticals.
By aligning capabilities and ambition with the signing of this agreement, the parties bring together their extensive experience in cell sourcing, regulations, bio-variability, product design, biocompatibility testing, preclinical and clinical testing.
In doing so they will deliver benefit to clients by helping to successfully navigate the complexities of the cell & gene therapy landscape.
Medical Technology Innovation Facility
The collective expertise of Anthony Nolan and MTIF will support the cost-effective development of new cell and gene therapies by offering a complete ‘bench to bedside’ service. This partnership will expedite the availability of much needed new lifesaving cell therapies.
Henny Braund, Chief Executive of Anthony Nolan says: “At Anthony Nolan we are delighted to collaborate with the MTIF, strengthening our ability to support our clients from early-stage development to commercialisation. Drawing on each of our strengths, we can help clients to advance their therapeutic pipeline.”
“Our mission, as always, is to improve and save the lives of patients around the world independent of their background. In partnering with the MTIF, we hope to be one step closer to this.”
Professor Mike Hannay, Managing Director of the Medical Technologies Innovation Facility (MTIF) says: “This is an exciting collaboration that will accelerate the development of innovative stem cell and gene therapies improving the lives of patients around the world.”
“Antony Nolan and MTIF together provide an unmatched capability right from sourcing high quality starting material through to the development and characterisation of your new medicine improving your chances of bringing a life-changing medicine to patients.”
Keep up to date with all the latest news from D2N2 by signing up to our Newsletter.
